ElevateBio Capacity Update May 2024: Cell & Gene Therapy

Development of well characterized, robust assays are key in the growing field of Cell and Gene therapy. With the increasing number of clinical applications and interest in the field, robust, scalable, and cost-effective platforms for rapid analytics are needed. Companies are seeking rapid turnaround times to get products to patients faster and ElevateBio BaseCamp’s development of platform analytics support a range of release testing for Cell and Gene therapy products.

In this presentation from the May 2024 OPCU event, we describe ElevateBio BaseCamp’s platform analytical offerings and development capabilities. From rapid safety testing to identity and characterization, BaseCamp offers solutions to reduce vein-to-vein times. Our analytics’ experts dive deeper into potency assay development including a case study for lentiviral vector potency assay development. BaseCamp is focused on delivering robust, reproducible assays to enabling our partners to understand and characterize their product throughout the entire lifecycle. Streamlining workflows through platform assays and early characterization accelerates our partner’s timelines with a seamless transition from analytical development to quality control for cGMP manufacturing. Join us to learn more directly from our analytical experts on ElevateBio BaseCamp’s capabilities and analytical services we offer today.